New Data in Early Settings and the Continued Development of Immunotherapies Captured Attention during ASCO's 2021 Annual Meeting. Among clinical topics, new data in early settings and continued development of immunotherapies stood out to oncologists as areas that can change their practice in the immediate future.
ESMO 2020 delivered data representing major progress in oncology, as oncologists grow more accustomed to the virtual format Oncologists are growing accustomed to attending the field’s major meetings virtually, with AACR, ASCO, and now ESMO 2020 having gone fully digital.While the virtual format has undoubtedly impacted attendees’ experiences and
Understanding the role of PSA In Prostate Cancer Oncologist-Patient Dialogue The prostate-specific antigen (PSA) score has become a critical post-diagnosis tool for oncologists as they discuss prostate cancer disease state with their patients along with their families and caregivers.Oncologist-patient relationships are based
ASCO20 Delivered Practice-Changing Data in a Highly Accessible, Virtual Format; Despite Reduced Levels of Engagement among Oncologists Despite the disruption and transition to a completely virtual format, 2020 was not an off-year for ASCO. Nearly all oncologists who attended this year’s ASCO Annual Meeting felt that it represented at
ASCO20 Moves From McCormick Place: Oncologists Prepare for a Virtual Meeting With the ASCO 2020 Annual Meeting just days away, oncologists are nearly universally planning to “attend” this year’s virtual meeting. However, their participation in the meeting will be less in real-time and
COVID-19 Telemedicine and Breast Cancer Patient Care during the COVID-19 Pandemic: Oncologists' Perspective COVID-19 has served as a catalyst for the rapid uptake of telemedicine across a range of therapeutic categories. Initially, physicians adopted telemedicine, despite uncertainty surrounding reimbursement, in order to ensure the safety of
ASH 2019: Hem-oncs share their perspective on the latest in MM and CLL treatment among other key topics Nearly 30,000 hematology specialists gathered for this year’s 2019 American Society of Hematology (ASH) annual meeting held Dec 7-10 in Orlando, Florida. This year’s conference delivered on its promise to
Getting ready for ASH 2019: Perspective from the ZoomRx hem-onc panel The ASH 2019 Annual Meeting kicks-off this Saturday (12/7) in Orlando. Our survey of 51 practicing hematologists-oncologists indicated a great deal of excitement and anticipation, as they prepare for the meeting.In
JAKs continue to capture attention, new MOAs stir excitement at ACR 2019 This year’s annual meeting held November 8-13 did not disappoint according to a ZoomRx survey with 35 rheumatologists who attended the conference.
Oncologists on ESMO 2019 and the Potential Impact of Key PARP Inhibitor Data Following this year’s ESMO annual meeting we asked a group of oncologists practicing in the US to weigh in on Europe’s biggest oncology conference. Oncologists expressed general excitement about the meeting,
Oncologists reflect on ASCO 2019 The data shared at this year's ASCO Annual Meeting moved the field of clinical oncology forward.Our survey with over 60 oncologists who attended the conference shows that ASCO 2019 did not disappoint.
Practicing Oncologists Weigh In on ASCO's 2019 Annual Meeting With ASCO just days away, oncologists are divided in their outlook for this year's meeting. In our survey of 54 practicing oncologists who plan on attending the conference, half (52%) reported they expect
Breakthrough Treatments and Pharma's Pricing Dilemma - Perspective from AAN 2019 The recent 2019 AAN conference (May 4-10, Philadelphia) brought promising new data in rare diseases, generating a great deal of excitement and anticipation for new therapies.
